PRPO – Precipio, Inc. As expected, the reverse split has been completed. So, how far down will we decline? While the company press releases have been positive over the last few months, the underlying fundamentals and financial environment that led to the slow decline, I believe, remains in place. Anticipated in the upcoming few weeks,…
It’s closing in on a year, March 25th to be exact, of Precipio’s stock price not meeting Nasdaq’s listing price requirement. And it’s now down to the wire for management to make good on their claim in avoiding a reverse split to remain listed on the exchange. So, what now? Apparently, the rumor is that…
According to Merriam-Webster, the definition of undervalue is a verb meaning: to value, rate, or estimate below the real worth. So does this apply to Precipio? At this current point in November, I would say it does. Precipio, Inc. is a growing company in the burgeoning liquid biopsy space that is visibly executing a strategy…
I’ve been watching the ebb and flow of the market, keeping an eye out for potential accelerated growth candidates and have identified a possible gem. This pick is Precipio, Inc. (PRPO). This small cap company is in the business of providing cancer diagnostic products and services to the oncology market. Precipio is expanding the potential…